Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24‐week, randomized, open‐label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)

Publisher： John Wiley & Sons Inc

E-ISSN： 1463-1326|17|12|1133-1141

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.17, Iss.12, 2015-12, pp. : 1133-1141

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT

By Strojek Krzysztof   Bebakar Wan M.W.   Khutsoane Duma T.   Pesic Milica   Šmahelová Alena   Thomsen Henrik F.   Kalra Sanjay  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 2887-2894

Informa Healthcare

Access to resources Recommend Favorite

Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes

By Yang Wenying   Xu Xiangjin   Liu Xiaomin   Yang Gangyi   Seino Yutaka   Andersen Henning   Jinnouchi Hideaki  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1599-1608

Informa Healthcare

Access to resources Recommend Favorite

Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials

By  

DIABETIC MEDICINE, Vol. 32, Iss. 5, 2015-05 ,pp. : 585-594

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 936-948

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 936-948

John Wiley & Sons Inc

Access to resources Recommend Favorite